Sailong Pharmaceutical GroupLtd Past Earnings Performance
Past criteria checks 1/6
Sailong Pharmaceutical GroupLtd's earnings have been declining at an average annual rate of -35%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 1.5% per year. Sailong Pharmaceutical GroupLtd's return on equity is 1.5%, and it has net margins of 2.6%.
Key information
-35.0%
Earnings growth rate
-35.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -1.5% |
| Return on equity | 1.5% |
| Net Margin | 2.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Sailong Pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 301 | 8 | 83 | 26 |
| 31 Dec 23 | 311 | 10 | 95 | 28 |
| 30 Sep 23 | 297 | -35 | 135 | 28 |
| 30 Jun 23 | 290 | -35 | 141 | 27 |
| 31 Mar 23 | 281 | -35 | 149 | 27 |
| 01 Jan 23 | 264 | -37 | 150 | 24 |
| 30 Sep 22 | 254 | -33 | 154 | 24 |
| 30 Jun 22 | 249 | -32 | 155 | 24 |
| 31 Mar 22 | 241 | -24 | 156 | 21 |
| 01 Jan 22 | 247 | -23 | 160 | 21 |
| 30 Sep 21 | 179 | -34 | 126 | 24 |
| 30 Jun 21 | 161 | -45 | 131 | 25 |
| 31 Mar 21 | 157 | -58 | 135 | 26 |
| 31 Dec 20 | 121 | -67 | 122 | 26 |
| 30 Sep 20 | 205 | -13 | 143 | 26 |
| 30 Jun 20 | 210 | -6 | 138 | 22 |
| 31 Mar 20 | 260 | 17 | 167 | 20 |
| 31 Dec 19 | 293 | 27 | 177 | 18 |
| 30 Sep 19 | 326 | 32 | 183 | 17 |
| 30 Jun 19 | 379 | 47 | 183 | 16 |
| 31 Mar 19 | 412 | 58 | 169 | 14 |
| 31 Dec 18 | 436 | 61 | 167 | 16 |
| 30 Sep 18 | 440 | 65 | 125 | 14 |
| 30 Jun 18 | 451 | 66 | 143 | 26 |
| 31 Mar 18 | 411 | 69 | 126 | 26 |
| 31 Dec 17 | 364 | 65 | 111 | 22 |
| 30 Sep 17 | 328 | 63 | 124 | 16 |
| 31 Dec 16 | 256 | 61 | 69 | 0 |
| 31 Dec 15 | 237 | 63 | 62 | 0 |
| 31 Dec 14 | 178 | 28 | 69 | 0 |
Quality Earnings: 002898 has a large one-off gain of CN¥13.2M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 002898 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002898's earnings have declined by 35% per year over the past 5 years.
Accelerating Growth: 002898 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 002898 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 002898's Return on Equity (1.5%) is considered low.